Compare MIST & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | VRCA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 88.0M |
| IPO Year | 2019 | 2018 |
| Metric | MIST | VRCA |
|---|---|---|
| Price | $0.36 | $3.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $4.14 | ★ $13.80 |
| AVG Volume (30 Days) | ★ 1.3M | 51.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | $210.30 | N/A |
| Revenue Next Year | $251.88 | $54.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.50 | $3.08 |
| 52 Week High | $3.06 | $9.82 |
| Indicator | MIST | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 24.59 | 43.75 |
| Support Level | N/A | $3.19 |
| Resistance Level | $0.84 | $5.94 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 0.00 | 26.55 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.